Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen and Clopidogrel DDI Study
NCT03392051Phase 1Completed
- Sponsor
- Akcea Therapeutics
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelacarsen in elevated lipoprotein(a) (Lp(a)) and cardiovascular diseases (CVD) (2 arms), sponsored by Akcea Therapeutics. Primary endpoint: Pharmacokinetics of Clopidogrel at 55 days. Started Dec 2017; status: completed.
02
Drugs
pelacarsen
03
Conditions
elevated lipoprotein(a) (Lp(a))cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT03392051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392051.